GLP-1 medication is not started at the dose it ends on. Both medicines are stepped up over months, four weeks at a minimum per step, and the reason is visible in their own adverse-reaction data: gastrointestinal reactions cluster at the increases. What is less well known is how consistent the schedules are — for both medicines, the milligram-and-week steps are numerically identical across the US, European and Singapore documents. The real divergence sits elsewhere, in what each document says a prescriber may do when a step is not tolerated. This article sets out both.
Dose titration: the planned sequence of increases from a starting dose to a maintenance dose, with a minimum time at each step. It is set out in the registered product information and applied by the prescriber, not adjusted by the patient.
Why the dose starts low and climbs in steps
Because the side effects are front-loaded onto the increases rather than spread evenly across treatment — GLP-1 safety: what is common, what is uncommon but serious, and when to stop and call a doctor sorts them by how a reader needs them.
Semaglutide's US prescribing information records nausea in 44% of adults on the injection product of treated adults against 16% on placebo, and states these reactions were most frequently reported during dosage escalation (prescribing information). Tirzepatide's runs nausea at 25–29% across doses against 8% on placebo, and goes further: the majority of nausea, vomiting and diarrhoea events occurred during dose escalation and decreased over time (prescribing information).
A schedule that parks someone at each dose for at least four weeks is built around exactly that pattern. It gives the body time at each level before the next demand, and it gives the prescriber a defined checkpoint at which to ask how the last four weeks went. The slow part is the design, not a delay in it. We cover what to do about the symptoms themselves in managing nausea on GLP-1.
The semaglutide schedule, and the ceiling Singapore does not have
The registered steps are four weeks each: 0.25 mg for weeks 1–4, 0.5 mg for weeks 5–8, 1 mg for weeks 9–12, 1.7 mg for weeks 13–16, then a 2.4 mg maintenance dose from week 17 (US prescribing information). The European summary of product characteristics gives a numerically identical table (EU SmPC), and so does Singapore's registered product information (Singapore NDF).
Four months to the maintenance dose, in other words, and the same four months in every jurisdiction checked.
One thing does differ, and it is the sort of detail that gets lost when a reader lands on an American page. The US document allows an increase beyond 2.4 mg to a maximum of 7.2 mg for patients who have tolerated 2.4 mg for at least four weeks (US prescribing information). The European document also allows 7.2 mg, explicitly gated to a BMI of 30 or above at the start of treatment (EU SmPC). Singapore's registered information has no such step: the escalation table ends at 2.4 mg maintenance (Singapore NDF).
So a dose discussed as available elsewhere is not on the Singapore-registered schedule at all.
The tirzepatide schedule
Tirzepatide is titrated on the same four-week rhythm but in even increments rather than a fixed table.
The US prescribing information gives 2.5 mg once weekly for four weeks as the starting dose, states that 2.5 mg is for initiation and is not approved as a maintenance dose, then increases to 5 mg, with further increases in 2.5 mg steps after at least four weeks on the current dose to a maximum of 15 mg (US prescribing information).
The European document states the same starting dose, the same 2.5 mg increments after a minimum of four weeks, and the same 15 mg adult maximum (EU SmPC). Singapore's registered product information gives the same numeric steps (Singapore NDF).
The numeric steps are the same across the three documents. What those documents cover is not the same — Singapore's registered tirzepatide product is registered for type 2 diabetes, so a Singapore reader should not take the comparison as a statement about which indications are approved here. That is a question for the prescribing doctor. Where GLP-1 dosing is concerned, the numbers travel better than most people assume — which makes the one place they do not travel worth reading carefully.
If a step is not tolerated, the two labels are not symmetrical
This is the asymmetry that matters most, and it is easy to miss because it is an absence rather than a difference.
Semaglutide. Every dosing section checked contains an explicit sentence permitting a delay. The US wording is to consider delaying dosage escalation for four weeks if a dose is not tolerated during escalation (US prescribing information). The European and Singapore wording is identical to each other and differently framed: consider delaying dose escalation or lowering to the previous dose until symptoms have improved (EU SmPC, Singapore NDF). Note what the second version adds — an option to step back down, and an open-ended duration rather than a fixed four weeks.
Tirzepatide. No equivalent sentence appears in the dosing section of the US, European or Singapore document (US prescribing information, EU SmPC, Singapore NDF).
Two things follow. First, "you can just pause the escalation" is not a GLP-1 class fact — it is written into one medicine's labelling and not the other's. Second, this is a fact about what the documents say rather than a ranking of the two medicines, and it is information for the prescriber rather than a licence for anyone to hold a dose on their own.
The maintenance dose is a choice, not automatically the maximum
Titration has an end point, and the end point is decided rather than assumed.
Tirzepatide's US label lists 5 mg, 10 mg and 15 mg as maintenance doses, instructs that treatment response and tolerability be considered when selecting one, and states that a lower maintenance dose should be considered if a patient does not tolerate the current one (prescribing information). That is the only tolerability lever anywhere in that document, and it operates after titration rather than during it.
At GetLean, our philosophy is that the medication is the catalyst rather than the plan, which is why the lowest dose that does the job is the interesting one — the months on the ramp are also the months to get eating and training in place, while appetite is still changing.
Individual circumstances vary, and clinical-trial figures describe the populations studied. Every part of this is your prescriber's decision: never raise, hold, lower or skip a dose on your own, and take a schedule from the person who wrote your prescription rather than from an article. If a step is going badly, that is a consultation, not a calculation.
The first step on that ramp is the one people ask about most. Your first GLP-1 injection covers what to expect from it, including why the pen's own steps come from the leaflet rather than from an article.
Common questions
How long does GLP-1 dose titration take?
For semaglutide, the registered schedule reaches the 2.4 mg maintenance dose after 16 weeks — four weeks each at 0.25, 0.5, 1 and 1.7 mg (Singapore NDF). For tirzepatide, it is 2.5 mg for four weeks, then 5 mg, then increases of 2.5 mg after a minimum of four weeks on the current dose (Singapore NDF). Your own pace is your prescriber's decision.
Why does the dose start so low?
Because gastrointestinal reactions cluster at the increases. Semaglutide's label records that they were most frequently reported during dosage escalation (prescribing information), and tirzepatide's states most nausea, vomiting and diarrhoea occurred during escalation and decreased over time (prescribing information).
Is the dosing schedule different in Singapore?
For the core steps, no — the milligram-and-week schedule is identical across the US, EU and Singapore documents for both medicines (Singapore NDF, Singapore NDF). One thing does differ: the US and EU documents allow semaglutide to be increased to 7.2 mg, and Singapore's does not (US PI, EU SmPC).
Can a dose increase be delayed if the current dose is not tolerated?
For semaglutide, the documents give the prescriber that option explicitly — the US wording is to consider delaying escalation for four weeks (US PI), and the EU and Singapore wording is to consider delaying escalation or lowering to the previous dose until symptoms have improved (Singapore NDF). Tirzepatide's dosing sections contain no equivalent sentence in any of the three (US PI, EU SmPC, Singapore NDF). Either way it is the prescriber's call.
Do you have to go all the way to the top dose?
No. Tirzepatide's US label lists 5 mg, 10 mg and 15 mg as maintenance doses and instructs that response and tolerability be considered when selecting one, with a lower maintenance dose considered if a higher one is not tolerated (prescribing information). The end point is a clinical choice rather than an automatic climb to the maximum.